Endogenous progenitor cell proliferation

Endogenous progenitor cell proliferation refers to the biological process and therapeutic strategy of stimulating resident stem or progenitor cells within adult tissues to divide and contribute to tissue repair or regeneration. Unlike exogenous cell therapy, which involves the transplantation of laboratory-expanded cells, this approach leverages the body's innate regenerative potential by pharmacological or biological modulation of signaling pathways such as Wnt/beta-catenin, Notch, and various growth factor cascades [1, 2, 10]. It is a critical target in regenerative medicine for treating conditions like stroke, spinal cord injury, and myocardial infarction, where natural repair mechanisms are insufficient [5, 6, 9]. Therapeutic agents that promote this process include growth factors like erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF), as well as small molecules targeting intracellular regulators like GSK-3 or AMPK [2, 5, 10]. However, therapeutic stimulation of progenitor cells carries risks, including potential tumorigenesis and the formation of non-functional or aberrant tissue architectures [1, 9].

Other names

Endogenous stem cell activationEndogenous neurogenesisIn situ tissue regenerationResident progenitor cell expansionEndogenous stem cell proliferation

Stimulation of intracellular signaling pathways (e.g., Wnt/beta-catenin, Notch, PI3K/Akt/mTOR, and MAPK) to activate the cell cycle and self-renewal programs of resident progenitor cells [2, 10, 12].